Senior Physician

Department of Oncology

Sharett Institute of Oncology

Hadassah University Hospital

Ein Karem, Jerusalem

Education/Training 

1976-1983 MD, Sackler School of Medicine, Tel Aviv University, Israel

1982-1983, Internship in Medicine,Assaf Harofeh Medical Center, Zerifin, Israel

A. Positions and Honors

Positions and Employment

1983-1986  Flight Surgeon, Israel Defense Forces.

1986-1993  Resident, Department of Dermatology, Beilinson Medical Center, Petah Tiqva, Israel

1993-1995  Resident, Department of Oncology, Beilinson Medical Center, Petah Tiqva, Israel

1995-2002  Senior Physician, Department of Dermatology, Hadassah University Hospital, Ein Karem, Jerusalem, Israel

1997-Present  Senior Physician, Sharett Institute of Oncology, Hadassah University Hospital, Ein Karem, Jerusalem, Israel

1997 - Instructor in Dermatology, Faculty of Medicine, Hebrew University, Israel

2000 - Lecturer in Dermatology and Oncology, Faculty of Medicine, Hebrew University, Israel

2002-2004  Research fellow, Surgery Branch, NCI, NIH, Bethesda MD

Other Experience and Professional Memberships

§         Israel Medical Association

§         Israel Dermatological Society

§         International Society of Cutaneous Lymphoma

B. Selected peer-reviewed publications

Alcalay J(PI), David M(C), Lotem M(C), Sandbank M(C) (1987):  Interferon and T-cell lymphoma. Ann Intern Med 107: 428.

Froom P (PI), Cyjon A(C), Lotem M(C), Ribak J(C), Gross M(C) (1988):Aircrew selection : a retrospective study. Aviat Space Environ Med 59 :1650167.

Weissman- Katzenelson V(PI), Lotem M(PI), Sandbank M(C) (1990):  Familial lichen planus. Dermatologica 180 : 166-168.

Halevy S(PI), Arieh(C)  R, Ingber A(C), Lotem M, Sandbank M(1990):  Analysis of lithogenous factors in lichen planus.  Acta Dermatovenereol 170:441-442.

Chisin R, Klein M, Freedman N, Mishani E, Shiloni E, Gimon Z, Lotem M(1998):  PET and Lymphoscintigraphic Evaluation of Malignant Melanomas. The Hadassah Hospital Experience. Clin Positron Imaging. Sep;1(4):252.

Klein M, Freedman N, Lotem M, Marciano R, Moshe S, Gimon Z, Chisin R(2000):  Contribution of whole body 18FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study. Nuklearmedizin 39:56-61. (language)

Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, Brookes S, Peters G, Lotem M, Zlotogorsky A, Landau M, Safro M, Shafir R, Friedman E, Peretz H(2000): Two p16(CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 8:590-6.

Lotem M , Hubert A,  Lyass A, Goldenhersh M,  Ingber A, Peretz T, Gabizon A(2000):  Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch       Dermatol 136:1475-1480.

Hazzan D, Reissmann P, Halak M, Resnick MB, Lotem M, Shiloni E(2001). Primary rectal malignant melanoma: report of two cases. Tech Coloproctol. Apr;5(1):51-4.

Lotem M, Peretz T, Drize O, Gimon Z, Ad EL D, Weitzen R, Goldberg H, Ben David I, Prus

D, Hamburger T, Shiloni E(2002): Autologous cell vaccine as a postoperative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). Br J Cancer. 86:1534-9.

Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O(2002): CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 168:2803-10.

Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD(2002): Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 146: 244-249.

Lotem M,  Antebi S, Peretz T, Ingber A and Prus D(2003): Mucosal melanoma of the female genitalia is a multifocal disorder of the entire squamous perineal epithelium Gynecol Oncol. Jan;88(1):45-50.

Lotem M, Gafni-Yehuda O, Butnariu E, Drize E, Peretz T, Abeliowitz D(2003): Evolution of clonal dominance in long term melanoma cell cultures. Cancer Genet Cytogenet Apr 15;142(2):87-91.

Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T(2004):  Interleukin-2 improves tumor responses to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer. Feb 23;90(4):773-80.

Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, Morag E, Bartfeld D, Lotem M, Peretz T, Pitcovski J(2004): Production and purification of melanoma gp100 antigen and polyclonal antibodies. Protein Expr Purif. Apr 34(2):183-9.

Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, Peretz T, Mandelboim O, Ben-Yehuda D(2003):  Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res. Oct 1;63(19):6340-9.

Hodak E, Gottlieb AB, Segal T, Maron L, Lotem M, Feinmesser M, David M(2004):  An open trial of climatotherapy at the dead sea for patch-stage mycosis fungoides. J Am Acad Dermatol. Jul;51(1):33-8.

Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, Peretz T, Pitcovski J(2004):  Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients. Immunol Lett. Jul 15;94(3):253-

Enk CD, Lotem M, Gimon Z, Hochberg M(2004):  Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res. Oct, 14(5):361-5.

Lotem M, Zhao Y, Riley JP, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR. (2006) Presentation of tumor antigens by dendritic cells genetically modified with viral and non viral vectors. J Immunother, 29(6):616-27.

Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, Bosshard W, Fiorentini G, Lotem M, Weitzen R, Keilholz U, Humblet Y, Piperno-Neumann S, Stupp R, Leyvraz S. 2006 Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. Apr;17(4):578-83.

Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. (2007)  MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells. Cancer Res 67:4499-506.

Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. (2007) Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res. 5:229-40.

Molho-Pessach V, Lotem M. (2007) Viral carcinogenesis in skin cancer. Curr Probl Dermatol  35:39-51.

Molho-Pessach V, Lotem M. (2007)Ultraviolet radiation and cutaneous carcinogenesis. Curr Probl Dermatol  35: 14-27.

Lotem M, Machlenkin A, Frankenburg S. Functional cytotoxicity of T cells at the tumor microenvironment. Review (submitted)

Machlenkin A, Uzana R., Frankenburg S., Pitcovski J., Nissan A., Gorodetsky R, Peretz T., Lotem M. Membrane Capture by Tumor-Reactive T Cells: A Novel Concept for Detection and Isolation of Functional Cytotoxic T Lymphocytes (submitted)

C. Research Support

Ongoing Research Support

2006-2007  Supporting organization: The Horowitz Foundation/  Title of research project: Membrane capture by antigen-specific T cells – a method to detect and isolate anti-tumor cytotoxic lymphocytes. 62,000$.  Role: PI

Completed Research Support

2005 - Supporting organization: Chief Scientist Israeli Ministry of Health.  Title of research project: Immunological evaluation of melanoma patients treated by autologous melanoma cell vaccine: Quantitative and qualitative analysis. $15,000.  Role: PI

2001-2003  Supporting organization: Cancer Treatment Research Foundation. Title of research project: Phase I/II study of dendritic cell vaccine with liposomal IL-2 for metastatic melanoma.  Role: PI

2001-2002  Supporting organization: Israel Cancer Association.  Title of research project: Treatment of Kaposi  sarcoma with ganciclovir and characterization of virological markers for monitoring the disease.  Role: PI

2000-2001  Supporting organization: The Horowitz Foundation Grant.  Title of research project: Development of a vaccine for metastatic melanoma using specific antigen-pulsed dendritic cells.  Role: PI

1999-2000  Supporting organization: The Horowitz Foundation Grant.  Title of research project: Development of a vaccine for metastatic melanoma using specific antigen-pulsed dendritic cells (DC) with and without liposome-encapsulated GM-CSF.  Role: PI

1999-2000  Supporting organization: Israel Cancer Association  Title of research project: Development of a vaccine for metastatic melanoma using specific antigen-pulsed dendritic cells (DC) with and without liposome-encapsulated GM-CSF.  Role: PI.